Moving Forward with General Pediatric Led Penicillin Allergy Delabeling

This review examines barriers that prevent general outpatient pediatric providers from delabeling patients with low-risk penicillin allergy. It provides a summary of current progress and offers insight into potential solutions to improve clinical implementation. Unverified penicillin allergy, often labeled in early childhood, are associated with adverse health outcomes and increased healthcare costs over time. Consequently, the focus has shifted to the general pediatric setting for identifying and delabeling low-risk allergy. This review concentrates on key factors influencing implementation in outpatient pediatrics, including the need for standardized, validated pediatric-specific protocols; the perceptions and education of patients and medical staff; environmental and social determinants of health; and economic and logistical challenges. This review identifies the primary obstacles to effective outpatient delabeling as knowledge gaps among providers, patient and family apprehension, systemic healthcare challenges, and disparities in allergy care resources. Overcoming these barriers will require a multi-faceted approach that includes structured education, the adoption of validated low-risk penicillin allergy delabeling strategies for pediatric patients, and policy-driven changes to healthcare delivery. These efforts are essential for improving outcomes for pediatric patients labeled with a history of penicillin allergy. This review provides practical insights and solutions to barriers faced in the general outpatient pediatric implementation of low-risk penicillin allergy delabeling.

Authors

Institutions

Publication Details

Journal
Current Treatment Options in Pediatrics
Published
2026-03-02
DOI
https://doi.org/10.1007/s40746-026-00368-6
Primary Topic
Drug-Induced Adverse Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Moving Forward with General Pediatric Led Penicillin Allergy Delabeling

Daniel A. Steigelman, David C. Mari, Kevin White
Current Treatment Options in Pediatrics
Drug-Induced Adverse Reactions
article

Moving Forward with General Pediatric Led Penicillin Allergy Delabeling

Daniel A. Steigelman, David C. Mari, Kevin White
article en

Abstract

This review examines barriers that prevent general outpatient pediatric providers from delabeling patients with low-risk penicillin allergy. It provides a summary of current progress and offers insight into potential solutions to improve clinical implementation. Unverified penicillin allergy, often labeled in early childhood, are associated with adverse health outcomes and increased healthcare costs over time. Consequently, the focus has shifted to the general pediatric setting for identifying and delabeling low-risk allergy. This review concentrates on key factors influencing implementation in outpatient pediatrics, including the need for standardized, validated pediatric-specific protocols; the perceptions and education of patients and medical staff; environmental and social determinants of health; and economic and logistical challenges. This review identifies the primary obstacles to effective outpatient delabeling as knowledge gaps among providers, patient and family apprehension, systemic healthcare challenges, and disparities in allergy care resources. Overcoming these barriers will require a multi-faceted approach that includes structured education, the adoption of validated low-risk penicillin allergy delabeling strategies for pediatric patients, and policy-driven changes to healthcare delivery. These efforts are essential for improving outcomes for pediatric patients labeled with a history of penicillin allergy. This review provides practical insights and solutions to barriers faced in the general outpatient pediatric implementation of low-risk penicillin allergy delabeling.

Current Treatment Options in PediatricsVol. 12(1)
Wilford Hall Ambulatory Surgical Center (US), Banner - University Medical Center Tucson (US)
Openalex Percentile: Top 38%
Drug-Induced Adverse Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.